FCGRT and autoimmune hemolytic anemia: FcRn inhibitors offer several advantages over current AIHA treatments: they are well-tolerated, have a rapid onset of action, minimize infection risk, and serve as effective steroid-sparing agents for patients who cannot tolerate long-term corticosteroid therapy.